Estrogen Receptor Expression in Atypical Hyperplasia: Lack of Association with Breast Cancer

Estrogen receptor (ER) is expressed in normal and malignant breast epithelium, and expression levels have been found to increase with age in normal breast epithelium but not in atypical hyperplasia (AH) and carcinoma in situ. Here we assess ER expression in AH and its association with later breast cancer. ER expression was assessed immunohistochemically in archival sections from 246 women with AH who had open benign breast biopsy from 1967 to 1991. The ACIS III (Dako) was utilized to calculate ER expression in all atypical foci. Using multivariate linear regression, we examined associations of ER expression with age at biopsy, indication for biopsy, type of atypia, number of atypical foci, involution status, and family history. Breast cancer risk across levels of ER expression was also assessed compared with the Iowa SEER control population. Among 246 women, 87 (35%) had atypical ductal hyperplasia (ADH), 141 (57%) had atypical lobular hyperplasia (ALH), and 18 (7%) had both. Forty-nine (20%) developed breast cancer (median follow-up of 14.4 years). Multivariate analysis indicated that type of atypia and age at diagnosis were significantly associated with ER percent staining and intensity (P < 0.05). ER expression was increased in women with ADH and/or those over age 55. ER expression did not significantly impact breast cancer risk in patients diagnosed with atypia. We found increasing ER expression in AH with increasing age. ER expression in AH does not further discriminate breast cancer risk in women with atypia. Cancer Prev Res; 4(3); 435–44. ©2011 AACR.

[1]  V. Vogel The NSABP Study of Tamoxifen and Raloxifene (STAR) trial , 2009, Expert review of anticancer therapy.

[2]  A. Lazaris,et al.  Immunohistochemical expression of estrogen receptors alpha and beta in lobular neoplasia , 2007, Virchows Archiv.

[3]  R. Vierkant,et al.  Stratification of breast cancer risk in women with atypia: a Mayo cohort study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Singletary,et al.  Expression of ERα and ERβ in lobular carcinoma in situ , 2007, Histopathology.

[5]  Romayne A. Thompson,et al.  Age-related lobular involution and risk of breast cancer. , 2006, Journal of the National Cancer Institute.

[6]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[7]  P. Thomas,et al.  Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in‐situ hybridization in the evaluation of HER‐2/neu expression in primary breast carcinoma , 2006, Histopathology.

[8]  S. Hilsenbeck,et al.  Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer , 2005, Breast Cancer Research.

[9]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[10]  V Shane Pankratz,et al.  Benign breast disease and the risk of breast cancer. , 2005, The New England journal of medicine.

[11]  K. Bloom,et al.  Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. , 2004, American journal of clinical pathology.

[12]  J. Sloane,et al.  Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. , 2002, The American journal of pathology.

[13]  E. Frenkel,et al.  Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. , 2001, American journal of clinical pathology.

[14]  S. Fuqua,et al.  Histological and biological evolution of human premalignant breast disease. , 2001, Endocrine-related cancer.

[15]  M. Mayo,et al.  Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. , 2000, Journal of the National Cancer Institute.

[16]  J. Daurès,et al.  Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors. , 2000, Human pathology.

[17]  J. Sloane,et al.  Estrogen receptor-positive proliferating cells in the normal and precancerous breast. , 1999, The American journal of pathology.

[18]  J. Sloane,et al.  Oestrogen receptor expression in the normal and pre‐cancerous breast , 1999, The Journal of pathology.

[19]  D. Long,et al.  Immunohistologic Analysis of Estrogen Receptor Expression in Breast Carcinoma Precursor Lesions , 1998 .

[20]  F. Schmitt,et al.  Multistep progression from an oestrogen-dependent growth towards an autonomous growth in breast carcinogenesis. , 1995, European journal of cancer.

[21]  J L Kelsey,et al.  Reproductive factors and breast cancer. , 1993, Epidemiologic reviews.

[22]  D. Page,et al.  Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. , 1992, Human pathology.

[23]  G. Colditz,et al.  A prospective study of benign breast disease and the risk of breast cancer , 1992, JAMA.

[24]  R. Coombes,et al.  Breast Estrogen and Progesterone Receptors in the Normal Female Updated Version , 2006 .

[25]  A. Howell Clinical evidence for the involvement of oestrogen in the development and progression of breast cancer , 1989 .

[26]  O. Petersen,et al.  Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. , 1987, Cancer research.

[27]  W. Dupont,et al.  Atypical hyperplastic lesions of the female breast: A long-term follow-up study , 1986 .

[28]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[29]  T. Akiyama,et al.  :A long term follow-up study , 1982 .

[30]  R. Simon,et al.  Estrogen receptor values in patients with benign breast disease , 1979, Cancer.